UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
VRAX
Virax Biolabs Group Limited
There isn't enough reported data to score VRAX yet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
VRAX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate VRAX's fundamentals.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
VRAX PE Valuation
VRAX has no meaningful PE right now: it lost money over the past year.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
VRAX Forward outlook
There aren't enough analyst estimates for VRAX to show an outlook.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
VRAX Earnings Per Share
VRAX and UNH do not have enough comparable growth data to identify a winner.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over VRAX in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
VRAX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $12.4K | +802% |
| Q3 2025 | $1.6K | -68% |
| Q1 2025 | $1.4K | -98% |
| Q3 2024 | $5K | -94% |
| Q1 2024 | $79.9K | +2753% |
| Q3 2023 | $76.5K | +1228% |
| Q1 2021 | $109.8K | +340% |
| Q3 2020 | $14K | -81% |
VRAX's revenue has slid since its 2021 peak: $12,423 last quarter, down 84% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -51515% | -46773 points |
| Q3 2025 | -160788% | -157251 points |
| Q1 2025 | -238317% | -85079 points |
| Q3 2024 | -58124% | -33114 points |
| Q1 2024 | -4743% | N/A |
| Q3 2023 | -3538% | N/A |
| Q1 2023 | -153238% | -152989 points |
| Q3 2022 | -25010% | -22357 points |
VRAX's operating margin was −51515% last quarter, down 46773 points from the same quarter a year ago.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
VRAX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.9M | -$1.9M |
| Q3 2025 | -$3.1M | -$898.3K |
| Q1 2025 | -$3M | +$248.4K |
| Q3 2024 | -$2.2M | +$2M |
| Q1 2024 | -$3.2M | -$1.2M |
| Q3 2023 | -$4.2M | -$1.9M |
| Q1 2023 | -$2.1M | -$1.5M |
| Q3 2022 | -$2.3M | -$2M |
VRAX has burned cash in almost every quarter: −$13M over the past year, against −$12M the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over VRAX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
VRAX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.3% | +16.2K shares |
| 1 year | +168% | +120K shares |
VRAX has 190,520 diluted shares, up 168% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q3 2025 | — |
| Q1 2025 | — |
| Q3 2024 | — |
| Q1 2024 | $85,500 |
| Q3 2023 | — |
| Q1 2023 | — |
| Q3 2022 | — |
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
VRAX Net Leverage
VRAX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
VRAX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.5 | Oversold |
| Stochastic | 3.7 | Oversold |
VRAX's weekly RSI is 29 (oversold) and its Stochastic is 4 (oversold).
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
VRAX PE vs Healthcare Sector
VRAX has no meaningful PE right now: it lost money over the past year.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over VRAX on trend strength, trading above more of its moving averages.
VRAX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.48 | 55% below |
| 20 week MA | $2.42 | 72% below |
| 50 week MA | $4.59 | 85% below |
| 100 week MA | $15.9 | 96% below |
| 200 week MA | $44.9 | 99% below |
VRAX is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over VRAX on returns for 2026, with the stronger performance.
VRAX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $2,585.0 | $142.5 | -94% |
| 2023 | $142.5 | $36.5 | -74% |
| 2024 | $36.5 | $52.5 | +44% |
| 2025 | $52.5 | $8.98 | -83% |
| 2026 YTD | $8.98 | $0.67 | -93% |
VRAX has finished lower in three of the last four years. It's down 93% so far in 2026.